Equities research analysts expect Synlogic, Inc. (NASDAQ:SYBX) to report earnings per share of ($0.30) for the current quarter, Zacks reports. Two analysts have made estimates for Synlogic’s earnings. The highest EPS estimate is ($0.29) and the lowest is ($0.31). Synlogic reported earnings of ($0.36) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 16.7%. The business is scheduled to report its next quarterly earnings results on Thursday, November 4th.
According to Zacks, analysts expect that Synlogic will report full-year earnings of ($1.24) per share for the current fiscal year, with EPS estimates ranging from ($1.31) to ($1.19). For the next year, analysts anticipate that the firm will post earnings of ($1.22) per share, with EPS estimates ranging from ($1.50) to ($0.99). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Synlogic.
Synlogic (NASDAQ:SYBX) last posted its quarterly earnings data on Thursday, August 12th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.01. The company had revenue of $0.25 million during the quarter, compared to the consensus estimate of $0.20 million.
Large investors have recently modified their holdings of the stock. Charles Schwab Investment Management Inc. purchased a new stake in shares of Synlogic in the 2nd quarter valued at approximately $68,000. Janney Montgomery Scott LLC purchased a new stake in shares of Synlogic in the 1st quarter valued at approximately $91,000. Flagship Harbor Advisors LLC lifted its position in shares of Synlogic by 227.8% in the 1st quarter. Flagship Harbor Advisors LLC now owns 59,000 shares of the biotechnology company’s stock valued at $211,000 after acquiring an additional 41,000 shares in the last quarter. Northern Trust Corp lifted its position in shares of Synlogic by 81.2% in the 2nd quarter. Northern Trust Corp now owns 68,865 shares of the biotechnology company’s stock valued at $268,000 after acquiring an additional 30,866 shares in the last quarter. Finally, State Street Corp purchased a new stake in shares of Synlogic in the 2nd quarter valued at approximately $292,000. Institutional investors and hedge funds own 56.00% of the company’s stock.
Shares of Synlogic stock traded up $0.03 on Tuesday, hitting $3.02. The company had a trading volume of 108,609 shares, compared to its average volume of 615,719. The business has a 50-day simple moving average of $3.04 and a 200-day simple moving average of $3.45. The company has a market cap of $158.17 million, a PE ratio of -2.17 and a beta of 1.87. Synlogic has a 52 week low of $1.78 and a 52 week high of $5.11.
Synlogic, Inc engages in the discovery and development of Synthetic Biotic medicines. It focuses in Phenylketonuria, Enteric Hyperoxaluria, Immuno Oncology solid tumors, inflammatory bowel disease, and vaccines and other inflammatory programs. The company was founded by Jim Collins and Tim Lu on August 28, 2017, and is headquartered in Cambridge, MA.
Read More: Analyst Ratings Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.